|
BMS-247550 in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on BMS-247550 in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. BMS-247550 in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors Clinical research trials and BMS-247550 in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including BMS-247550 in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors. BMS-247550 in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a BMS-247550 in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors clinical trial. Participants oftentimes recieve the finest healthcare available for their BMS-247550 in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > BMS-247550 in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors  BMS-247550 in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
BMS-247550 in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
For Condition: ovarian germ cell tumor,extragonadal germ cell tumor,adult brain tumor,Testicular Cancer
Status: Recruiting
Sponsor(s): Memorial Sloan-Kettering Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy such as BMS-247550 use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have germ cell tumors that are refractory to cisplatin.
Details: OBJECTIVES: - Determine the efficacy of BMS-247550 in patients with advanced cisplatin-refractory germ cell tumors. - Determine the safety of this drug in these patients. OUTLINE: Patients receive BMS-247550 IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 20-58 patients (10-29 per group) will be accrued for this study within 2-3 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 16 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed germ cell tumor (GCT) (seminoma or non-seminoma) meeting criteria for 1 of the following: - Measurable metastatic disease by radiography - If eligibility is defined by measurable disease only, there must be at least 1 site that has not been previously irradiated - Alpha-fetoprotein greater than 15 ng/mL and/or ß-human chorionic gonadotropin greater than 2.2 mIU/L - Previously treated disease meeting criteria for 1 of the following groups: - Primary mediastinal nonseminomatous GCT AND failed 1 prior cisplatin-based regimen - Primary refractory GCT after 1 cisplatin-based regimen, defined as minimal or no response to initial therapy - Poor candidate for conventional or high-dose salvage therapy due to comorbid medical conditions AND failed 1 prior cisplatin-based regimen - Not a candidate for potentially curative therapy OR has already received high-dose chemotherapy regimens (prior paclitaxel allowed) - Deemed to be cisplatin-refractory after more than 1 prior regimen AND does not want to have potentially curative high-dose therapy PATIENT CHARACTERISTICS: Age - 16 and over Performance status - Karnofsky 70-100% Life expectancy - Not specified Hematopoietic - Absolute neutrophil count at least 1,500/mm^3 - Platelet count greater than 100,000/mm^3 - Hemoglobin at least 10 g/dL Hepatic - Bilirubin no greater than 1.5 times normal - SGOT no greater than 2 times upper limit of normal Renal - Creatinine no greater than 2.2 mg/dL Other - Not pregnant or nursing - Negative pregnancy test - No active infection PRIOR CONCURRENT THERAPY: Biologic therapy - No concurrent immunotherapy Chemotherapy - See Disease Characteristics - No other concurrent cytotoxic chemotherapy Endocrine therapy - Not specified Radiotherapy - See Disease Characteristics - No concurrent radiotherapy Surgery - Not specified Other - No other concurrent experimental or commercial anticancer medications or therapies
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RobertMotzer, Principal Investigator, Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center *Recruiting*
New York City, New York, 10021
United States
Recruiting Dean Bajorin 646-422-4333
Additional Information:
Study ID Numbers: CDR0000329992; MSKCC-03041,NCI-6022
Study Start Date:
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00070096
Other Ovarian Germ Cell Tumor Studies:
1. BMS-247550 in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
2. Screening for Cancer of the Prostate, Lung, Colon, Rectum, or Ovaries in Older Patients
3. Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer
4. Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer
Related Studies:
Other ovarian germ cell tumor Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
BMS-247550 in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
|
|
|
|
|
|
|
|
